• Contera Pharma has developed new strategies to identify drug development projects characterized by high probability of success, fast access to clinical development and long exclusivity.

  • Indications

  • Movement disorders are a group of diseases that affect the ability to produce and control body movement, and are often associated with neurological disorders or conditions associated with neurological dysfunction. One example of a movement disorder is dyskinesia which characterized by various involuntary movements, which can affect discrete body parts or can become generalized and severely disabling.

  • Projects

  • Contera Pharma develops new innovative treatments of movement disorders. The lead project JM-010 is approved to start Phase IIa studies for treatment of L-DOPA induced dyskinesia. Contera Pharma in addition, explores preclinical projects to treat or prevent other movement disorders like Parkinson's disease and tardive dyskinesia.